Senators question whether Pfizer, Eli Lilly telehealth platforms violate law

Nicole DeFeudis

Editor

Four senators want to know more about Pfizer and Eli Lilly’s partnerships with telehealth providers, and whether that may lead to inappropriate prescribing.

In two …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Senators question whether Pfizer, Eli Lilly telehealth platforms violate law

Nicole DeFeudis

Editor

Sign up to read this article for free.

Updated: Pfizer's activist says board must 'hold management accountable' for R&D shortcomings

Ahead of Novo’s CagriSema readout, Lilly returns to a promising new class of obesity drugs

Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Roche, Genentech end anti-tau Alzheimer’s drug collaboration with UCB

Editas pivots away from ex vivo sickle cell therapy in favor of in vivo approach

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Sen­a­tors ques­tion whether Pfiz­er, Eli Lil­ly tele­health plat­forms vi­o­late law

Nicole DeFeudis

Editor

Sign up to read this article for free.

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Ahead of No­vo’s Ca­griSe­ma read­out, Lil­ly re­turns to a promis­ing new class of obe­si­ty drugs

Sang­amo to seek ac­cel­er­at­ed ap­proval for Fab­ry gene ther­a­py, claims it won't need con­fir­ma­to­ry study

Roche, Genen­tech end an­ti-tau Alzheimer’s drug col­lab­o­ra­tion with UCB

Ed­i­tas piv­ots away from ex vi­vo sick­le cell ther­a­py in fa­vor of in vi­vo ap­proach

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

Senators question whether Pfizer, Eli Lilly telehealth platforms violate law

Updated: Pfizer's activist says board must 'hold management accountable' for R&D shortcomings

Ahead of Novo’s CagriSema readout, Lilly returns to a promising new class of obesity drugs

Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Roche, Genentech end anti-tau Alzheimer’s drug collaboration with UCB

Editas pivots away from ex vivo sickle cell therapy in favor of in vivo approach

IDEAYA Biosciences: Targeting unmet market needs with precision oncology